Therapeutics targeting CTLA-4 or PD-1/PD-L1 have achieved obvious outcomes in advanced HCC, but they are limited when used in combination because of immune-related adverse events, such as hepatitis (40). Here, CTLA4 is linked to hepatitis A virus infection.